secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2025-12-12T23:59:59+00:00
Accession:  0001171843-25-007909
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst gets FDA approval for ORLADEYO oral pellets for HAE patients aged 2 to <12 years
--------------------------------------------------------------------------------

- FDA approved ORLADEYO oral pellet formulation for prophylactic therapy in HAE children aged 2 to <12 years.
- First and only oral prophylactic treatment for this age group; previously only injectable options were available.
- Approval supported by APeX-P trial interim data showing early and sustained attack rate reductions with no new safety signals.
- BioCryst plans EU, Japan, and other regulatory filings; ORLADEYO capsule already approved for ages 12+ since Dec 2020.
- More than 3,500 patients in the US have been prescribed ORLADEYO to date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184325007909/0001171843-25-007909-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184325007909/f8k_121225.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-007909

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer